AMRX
Amneal Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Señales de momentum (gestores comparables):
amplitud de titulares +30.0% ·
flujo de acciones +2.4% ·
nuevas posiciones netas +20.0%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q1 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 106.56M | $1.84B | +7 | −10 |
| Q1 2026 | 107 | -1 | 100.53M | $1.25B | +9 | −11 |
| Q4 2025 | 109 | 0 | 106.30M | $1.34B | +1 | — |
| Q3 2025 | 18 | 0 | 61.16M | $612.26M | — | — |
| Q2 2025 | 15 | -1 | 52.63M | $425.79M | — | −1 |
| Q1 2025 | 13 | +3 | 21.14M | $177.14M | +3 | — |
| Q4 2024 | 10 | -1 | 20.64M | $163.48M | — | −1 |
| Q3 2024 | 10 | 0 | 16.87M | $140.36M | +2 | −2 |
| Q2 2024 | 10 | — | 16.56M | $105.19M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 7.49M | -16.6% | $62.78M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 7.49M | -16.6% | $62.78M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (pasivo) | 3.83M | +0.3% | $32.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (pasivo) | 3.83M | +0.3% | $32.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (pasivo) | 3.69M | -0.2% | $30.93M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 2.09M | +57.6% | $17.49M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 1.79M | +16.4% | $15.03M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 624.70K | -9.0% | $5.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 446.00K | Nuevo | $3.74M | 0.0% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 167.70K | Nuevo | $1.41M | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 126.68K | +30.3% | $1.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 52.67K | -40.1% | $441,366 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 15.84K | Nuevo | $132,706 | 0.0% | New | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Point72 Asset Management | $3.74M | 0.0% |
| Two Sigma Investments | $1.41M | 0.0% |
| D. E. Shaw & Co. | $132,706 | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 314 tenedores, 158.91M acciones, $1.92B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 50.00K acc. · $882,000
Officer · 146.40K acc. · $2.56M
Officer · 210.00K acc. · $3.65M
Officer · 6.61K acc. · $117,050
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología
17.6% de clase · Ver presentación original ante la SEC ↗
8.4% de clase · Ver presentación original ante la SEC ↗
9.4% de clase · Ver presentación original ante la SEC ↗